Related Experiment Video
Updated: Jan 10, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis
Jun Cao1, Zhichao Tan2, Enyu Yang3
1Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Department of Head and Neck and Rare Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, 310022, China.
Objectives:
Primary cardiac sarcomas (PCSs) are uncommon malignant tumors with a poor prognosis. This study aims to present the clinical characteristics and treatment outcomes for PCS observed in our centers.
Method:
We retrospectively gathered records of patients diagnosed with PCS at Peking University Cancer Hospital and Zhejiang Cancer Hospital between 2016 and 2023. Clinicopathological data, treatments, and outcomes were included in the analysis.
Result:
Between January 2016 and October 2023, a total of 26 patients with primary cardiac sarcoma were included in this study, with a majority being female (57.7%). The median age of the patients was 38.5 years, ranging from 15 to 82 years. The median overall survival (OS) for all patients was 18.7 months (95% CI: 16.2-25.4). Patients with normal baseline LDH levels had a significantly longer median OS of 25.4 months compared to 12.9 months for those with elevated LDH levels (p < 0.01). The median OS for patients who underwent R0 resection was 23.7 months, while it was 16.9 months for those who underwent R1/R2 resection, and 11.6 months for those who did not undergo surgery. Patients who received anthracycline-based chemotherapy seem to have better survival outcomes compared to those who received paclitaxel-based chemotherapy (mOS for chemotherapy 11.3 vs. 8.97 months, p = 0.25), but there was no statistical difference. First-line treatment with antiangiogenic agents or immunotherapy may enhance survival, with statistical significance observed.
Conclusion:
PCS presents a complex management challenge. Complete surgical resection remains the primary treatment option when feasible. Systemic treatment options, including chemotherapy, targeted therapy, and immunotherapy, may also improve survival outcomes.
